Firm says success of the IPO is a “testament to the focus and hard work of the management team”
Gadens has advised lung imaging specialist 4DMedical Limited on its $55.79 million initial public offering (IPO) and successful listing on the Australian Securities Exchange (ASX).
4DMedical’s technology provides four-dimensional respiratory analysis, enabling highly detailed maps of patients’ lung function. The technology is non-invasive and improves the ability of physicians to diagnose and manage lung diseases.
In a statement, Gadens said that it worked closely with the management team and board at 4DMedical on successful completion of the IPO and ASX listing.
“The IPO was completed ahead of schedule in response to high demand, with the money raised directed toward product research and advancing technology,” Gadens said.
Gadens partner Jol Rogers led the IPO process with partner James Beckley, supported by Melissa Phillips (senior associate) and William Zhang (associate). Meanwhile, partner Brett Feltham supported on specialist employment issues.
“It was a pleasure working with the 4DMedical team and its other advisers on this important moment in the company’s history,” said Rogers. “The success of the IPO in challenging economic times is a testament to the focus and hard work of the management team. We wish 4DMedical every success and look forward to working with the business in its new life as a listed company.”
Andreas Fouras, chief executive officer of 4DMedical, said that his firm was “pleased to work closely again with Gadens,” adding that the Gadens team “did an exceptional job to support completion of our IPO in difficult market conditions and on an ever compressing timeframe.”
“We have been delighted with the high level of support and interest we have received throughout this process and welcome this significant milestone of becoming a listed company after 15 years of hard work,” said Fouras. “4DMedical is focused on its mission to improve global health by providing unique and non-invasive imaging technologies that enable unprecedented insight into pulmonary function. Continued growth of the business is a priority, and we are eager to reward our supportive shareholders by delivering long-term value creation."
